26
nanotimes
Companies
Facts
million, largely due to changes in costs accrued with respect to litigation reserves due to the settlement of litigation with Hansen Medical.
For the full year, revenues declined by 6%, from $36.9 million in 2008 to $34.6 million in 2009. Net loss increased from $6.3 million in 2008 to $20.4 million in 2009 due to the costs, including impair- ment of intangible assets, recognized in connection with the company‘s litigation with Hansen Medical and reorganization during 2009. Adjusted EBITDA excluding litigation and bankruptcy related costs improved from $0.3 million in 2008 to $2.3 million in 2009.
http://www.lunainnovations.com
F
or the three months and full year ended De- cember 31, 2009, Metabolix (NASDAQ: MBLX)
reported a net loss of $9.8 million or $0.39 per share for the fourth quarter of 2009 as compared to a net loss of $8.9 million or $0.40 per share for the fourth quarter of 2008. For the full year, the Company re- ported a net loss of $38.0 million or $1.62 per share as compared to a net loss of $36.0 million or $1.58 per share for 2008. The Company‘s net cash used for operating activities during the fourth quarter of 2009 was $5.9 million, which compares to net cash used of $3.7 million for the comparable quarter in 2008. Net cash used in operating activities for the full year 2009 was $25.8 million compared to $18.4 million for 2008. Unrestricted cash and short-term invest- ments at December 31, 2009 totaled $92.2 million, which included net proceeds of $29.1 million from an equity offering completed in the fourth quarter. The Company continues to have no debt.
http://www.metabolix.com
Metagenomix is an early-stage biotechnology
company developing novel methods of screening microbes for pharmacologically active compounds.
Among the indications under investigation are can- cer, inflammation and infectious diseases including fungal infections and malaria. The technology also has applications in agriculture.
http://www.ctinnovations.com
M
agForce Nanotechnologies (MF6.FSE) has signed a Standby Equity Distribution Agree-
ment („SEDA“) with YA Global Master SPV Ltd. („YA
Global“), an investment fund managed by Yorkville Advisors. Under this agreement, MagForce now has the option over the next 36 months to avail itself of a binding commitment by YA Global to subscribe to and purchase multiple tranches of newly issued shares from the company’s approved capital up to a total amount of EUR20 million. MagForce will retain com- plete discretion over if and when it makes use of its rights over the life of the option.
C
onnecticut Innovations (CI), the state’s quasi-public authority responsible for technolo-
gy investing and innovation development, has made a $350,000 investment in Metagenomix Inc. of Branford, Connecticut, through its Eli Whitney Fund. This investment is part of a $700,000 minimum seed round also involving Elm Street Ventures and an individual investor. The investment represents CI’s twelfth in early-stage Connecticut technology compa- nies since the fiscal year began in July. Utilizing tech- nology licensed from Yale University, Metagenomix is developing innovative, high-throughput methods to synthesize novel compounds produced by bacteria in the soil and screen them for drug-like activity.
10-04 :: April 2010
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87